Overall, a significant negative effect of increased total CD44 expression on chemotherapy treatment outcome was observed across several types of cancers, including breast, colorectal and head and neck cancers measured typically through overall survival (OS) and recurrence-free survival (RFS) values, as well as through response to chemotherapy (Wu et al., 2024). The gene discussed is CD44; the disease is cancer.